Loading stock data…
$1.93-0.06 (-3.23%)
Neuronetics, Inc.
Neuronetics, Inc. in the Healthcare sector is trading at $1.93 with a market capitalization of $232M. Wall Street consensus targets $5.75 (4 analysts), implying a +198.5% move over the next 12 months. The stock is currently 44% below its 52-week high of $3.44, remaining 4.1% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 5 is oversold, raising the odds of a near-term bounce. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $41.57M↑ | $34.45M↓ | $41.78M↑ | $37.30M↓ | $38.11M |
| Gross Profit | $21.22M↑ | $16.15M↓ | $21.70M↑ | $17.11M↓ | $17.76M |
| Operating Income | -$1.50M↑ | -$8.99M↓ | -$5.04M↑ | -$7.32M↑ | -$8.06M |
| Net Income | -$3.44M↑ | -$10.79M↓ | -$7.16M↑ | -$9.04M↑ | -$10.12M |
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatme...